Stock comparison
IDEXX Laboratories
Regeneron Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
REGN
Regeneron Pharmaceuticals
Market cap
$65.82B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | REGN | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 64C | IDXX |
| Benjamin Graham | 80A | 68B | IDXX |
| Philip Fisher | 75B | 48D | IDXX |
| Peter Lynch | 71B | 26F | IDXX |
| Joel Greenblatt | 83C | 45D | IDXX |
| Charlie Munger | 87A | 59C | IDXX |
| Terry Smith | 84A | 57C | IDXX |
Side-by-side metrics
| Metric | IDXX | REGN |
|---|---|---|
| Market cap | $44.12B | $65.82B |
| P/E (TTM) | 39.0x | 16.4x |
| EV/EBIT | 31.6x | 20.0x |
| ROIC (TTM) | 40.66% | 8.53% |
| Gross margin | 62.05% | 84.55% |
| Net margin | 24.63% | 29.65% |
| Revenue CAGR 5y | 7.56% | -2.81% |
| EPS CAGR 5y | 10.79% | -13.35% |
| Debt / Equity | 0.7x | 0.1x |
| Dividend yield | 0.0% | 0.51% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- EPS CAGR 5y10.79%vs -13.35%+181%
- Revenue CAGR 5y7.56%vs -2.81%+137%
- ROIC (TTM)40.66%vs 8.53%+79%
REGN leads on
- Dividend yield0.51%vs 0.0%+100%
- Debt / Equity0.1xvs 0.7x+88%
- P/E (TTM)16.4xvs 39.0x+58%
- EV/EBIT20.0xvs 31.6x+37%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.